Internal Medicine · Royal Oak, MI
NPI
1932462637
Since 2012
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3601 W 13 Mile Rd
Royal Oak, MI, 48073
Phone (248) 551-3000
Groups this clinician bills Medicare through
Medicare paid, 2024
$217K
3,178 services
Medicare patients, 2024
1,449
Average age 77
Drug cost, 2024
$3.0M
5,896 prescriptions
Company payments, 2025
$14K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joel Skaistis was code 99232 (hospital e&m - subsequent), 863 times for 271 patients. In total Joel Skaistis billed 3,178 services in 53 codes, and Medicare paid $217K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-06-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 863 | 271 | $63.49 | $55K |
| 93306 Echocardiography (TTE/TEE) | Facility | 604 | 589 | $53.44 | $32K |
| 99214 Office E&M - Established | Office | 335 | 186 | $92.64 | $31K |
| 93000 Electrocardiogram | Office | 128 | 111 | $9.68 | $1,239 |
| J2785 Injection, regadenoson, 0.1 mg | Office | 124 | 31 | $3.05 | $378 |
| 99222 Hospital E&M - Initial | Facility | 103 | 97 | $105.66 | $11K |
| 75574 CT/CTA - Chest | Facility | 97 | 97 | $88.17 | $8,553 |
| 99223 Hospital E&M - Initial | Facility | 95 | 89 | $136.58 | $13K |
| A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 60 | 30 | $87.10 | $5,226 |
| 93306 Echocardiography (TTE/TEE) | Office | 57 | 57 | $131.92 | $7,520 |
| 99231 Hospital E&M - Subsequent | Facility | 55 | 42 | $40.24 | $2,213 |
| 93015 Electrocardiogram | Office | 52 | 52 | $49.13 | $2,555 |
| 75561 MRI/MRA - Other | Facility | 49 | 48 | $89.26 | $4,374 |
| 99204 Office E&M - New | Office | 41 | 41 | $121.36 | $4,976 |
| 75572 CT/CTA - Chest | Facility | 37 | 37 | $65.00 | $2,405 |
By year: 2022 $203K for 3,759 services; 2023 $233K for 3,570 services; 2024 $217K for 3,178 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joel Skaistis prescribed most often to Medicare patients was Atorvastatin Calcium, with 636 prescriptions and refills. In total Joel Skaistis wrote 5,896 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 636 | 1,683 | 239 | $9,325 |
| Metoprolol Succinate Generic | 432 | 1,157 | 166 | $7,312 |
| Jardiance Empagliflozin | 326 | 729 | 116 | $402K |
| Eliquis Apixaban | 321 | 753 | 113 | $416K |
| Losartan Potassium Generic | 297 | 848 | 120 | $4,340 |
| Ezetimibe Generic | 287 | 805 | 116 | $6,700 |
| Clopidogrel Clopidogrel Bisulfate | 270 | 712 | 99 | $4,820 |
| Repatha Sureclick Evolocumab | 246 | 274 | 51 | $148K |
| Eplerenone Generic | 185 | 440 | 78 | $16K |
| Amlodipine Besylate Generic | 184 | 470 | 70 | $1,559 |
| Entresto Sacubitril/Valsartan | 181 | 379 | 57 | $238K |
| Spironolactone Generic | 155 | 439 | 58 | $1,876 |
| Ozempic Semaglutide | 135 | 188 | 37 | $155K |
| Furosemide Generic | 118 | 271 | 62 | $737 |
| Flecainide Acetate Generic | 113 | 235 | 40 | $4,989 |
Brand drugs: 1,834 claims; generic drugs: 4,062 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joel Skaistis $14K ($14K in general payments such as food, travel and fees) from 14 companies. The largest payer was Pfizer Inc. with $13K.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 16 | $13K |
| Alnylam Pharmaceuticals Inc. ALNY | 16 | $285 |
| Novartis Pharmaceuticals Corporation NVS | 12 | $182 |
| E.R. Squibb & Sons, L.L.C. BMY | 10 | $159 |
| Merck Sharp & Dohme LLC MRK | 6 | $156 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $140 |
| Novo Nordisk Inc NVO | 5 | $104 |
| Amgen Inc. AMGN | 3 | $58.86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $48.59 |
| Actelion Pharmaceuticals US, Inc. JNJ | 1 | $30.56 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.